Halozyme Therapeutics (HALO) Financial Analysis & Valuation | Quarter Chart

Halozyme Therapeutics (HALO)

HALO
Price: $77.18
Fair Value: 🔒
🔒score
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) ... more
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States... more
Description Shares
Market Cap$9.15BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOHelen I. Torley
IPO Date2004-03-16CAGR0.58%
Employees350Websitewww.halozyme.com
Div. Yield—Payout Ratio—
Buy Back Yield3.44%Total Yield3.44%
HALO chart loading...
Fundamentals Technicals
Enterprise Value$10.39BP/E Ratio16.71
Forward P/E7.8PEG Ratio0.87
P/S Ratio6.55P/B Ratio44.84
P/CF Ratio14.55P/FCF Ratio14.8
EPS$4.62EPS Growth 1Y-26.06%
EPS Growth 3Y112.21%EPS Growth 5Y146.02%
Revenue Growth 1Y39.12%Gross Margin0.77%
Operating Margin0.57%Profit Margin0.23%
ROE1.26%ROA0.13%
ROCE0.37%Current Ratio2.76
Quick Ratio2.33Cash Ratio0.85
Debt/Equity9.76Interest Coverage44.97
Altman Z Score4.23Piotroski Score6

View Halozyme Therapeutics financial charts →